Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eyestem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyestem to Begin Human Trials for its Pioneering Dry AMD Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"INDIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Eyestem

    Menu

    Eyestem

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Eyestem

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eyestem to Begin Human Trials for its Pioneering Dry AMD Treatment

              Details:

              Eyecyte RPE, is a lost or damaged retinal pigment epithelium cells replacement therapy is being investigated for the treatment geographic atrophy arising from dry age-related macular degeneration

              Lead Product(s): iPSC-derived Therapy

              Therapeutic Area: Ophthalmology Product Name: Eyecyte-RPE

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 02, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY